Concord Biotech Ltd Technical Momentum Shifts Signal Bullish Outlook

Technical Trend Evolution and Price Movement

As of 18 Sep 2026, Concord Biotech’s share price closed at ₹1,462.10, marking a modest gain of 0.55% from the previous close of ₹1,454.15. The stock traded within a range of ₹1,441.25 to ₹1,473.85 during the session, maintaining proximity to its 52-week high of ₹1,702.10 while comfortably above the 52-week low of ₹987.05. This price action reflects a consolidation phase with a positive bias, supported by the recent upgrade in technical trend from mildly bullish to bullish.

The daily moving averages have turned decisively bullish, indicating that short-term momentum is favouring buyers. This is a critical development as moving averages often act as dynamic support and resistance levels, and their bullish alignment suggests sustained buying interest. The stock’s ability to hold above these averages enhances confidence in a potential upward trajectory.

MACD and Momentum Indicators

The MACD indicator presents a nuanced picture. On a weekly basis, the MACD is bullish, signalling that momentum is gaining strength over the medium term. However, the monthly MACD remains mildly bearish, indicating some caution among longer-term investors. This divergence suggests that while short- and medium-term momentum is improving, the longer-term trend has yet to fully confirm a sustained uptrend.

Relative Strength Index (RSI) readings on both weekly and monthly charts currently show no clear signal, hovering in neutral zones. This implies that the stock is neither overbought nor oversold, providing room for further price appreciation without immediate risk of a technical pullback.

Bollinger Bands and Volatility

Bollinger Bands analysis reveals a mildly bullish stance on the weekly chart and a bullish signal on the monthly chart. The bands are expanding slightly, which typically indicates increasing volatility and the potential for a breakout. The stock’s price is currently near the upper band on the weekly timeframe, suggesting upward momentum but also signalling that investors should monitor for any signs of short-term exhaustion.

Other Technical Indicators and Trend Assessments

The Know Sure Thing (KST) indicator presents a bearish signal on the weekly chart, which contrasts with the bullish signals from MACD and moving averages. This divergence suggests some short-term caution, possibly reflecting profit-taking or consolidation phases. The monthly KST reading is not available, limiting longer-term interpretation.

Dow Theory analysis on both weekly and monthly timeframes indicates no clear trend, highlighting the stock’s current phase of indecision or transition. Similarly, On-Balance Volume (OBV) shows no discernible trend, suggesting that volume flows have not yet decisively confirmed the price momentum.

Comparative Returns and Market Context

Concord Biotech’s recent returns outperform the broader Sensex benchmark across several timeframes. Over the past week, the stock gained 0.65% while the Sensex declined by 0.79%. Over one month, Concord’s loss of 3.39% was less severe than the Sensex’s 4.39% decline. Year-to-date, the stock has delivered a robust 8.67% return compared to the Sensex’s negative 12.80%. However, over the last year, Concord’s share price has declined by 10.62%, slightly worse than the Sensex’s 10.13% fall.

Longer-term performance is more encouraging, with a three-year return of 44.24% significantly outpacing the Sensex’s 9.55% gain. This outperformance underscores Concord Biotech’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector, despite short-term volatility.

Mojo Score and Rating Upgrade

MarketsMOJO has upgraded Concord Biotech’s Mojo Grade from Sell to Hold as of 31 Jul 2026, reflecting improved technical and fundamental outlooks. The current Mojo Score stands at 57.0, signalling a neutral stance with potential for further improvement. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology industry, which often entails higher volatility but also greater growth opportunities.

Investment Implications and Outlook

The recent technical parameter changes suggest that Concord Biotech is entering a phase of positive momentum, supported by bullish daily moving averages and weekly MACD signals. Investors should note the mixed signals from KST and monthly MACD, which counsel a degree of caution and the need for confirmation of sustained trends.

Given the stock’s relative outperformance against the Sensex over multiple periods and its upgraded Mojo Grade, Concord Biotech may appeal to investors seeking exposure to the pharmaceutical sector’s growth potential with a balanced risk profile. Monitoring the RSI and Bollinger Bands for signs of overextension will be crucial in the coming weeks.

Conclusion

Concord Biotech Ltd’s technical landscape is showing encouraging signs of bullish momentum, particularly on shorter timeframes. The upgrade in technical trend and Mojo Grade from Sell to Hold reflects a more constructive outlook, supported by positive price action and relative strength versus the broader market. While some indicators advise caution, the overall technical and fundamental picture suggests that the stock is well-positioned for potential gains in the near to medium term.

Investors should continue to monitor key technical signals such as MACD, RSI, and Bollinger Bands, alongside broader market conditions and sector developments, to make informed decisions. Concord Biotech’s small-cap status and sector dynamics offer both opportunities and risks, making disciplined analysis essential.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today